- Home
- CHNR vs LABT Comparison
CHNR vs LABT Comparison
Compare CHNR & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | LABT |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.3M |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CHNR | LABT |
|---|---|---|
| Price | $3.95 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 333.3K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $1.66 |
| 52 Week High | $8.20 | $6.85 |
Technical Indicators
Market Signals| Indicator | CHNR | LABT |
|---|---|---|
| Relative Strength Index (RSI) | 58.39 | 39.04 |
| Support Level | $3.93 | N/A |
| Resistance Level | $4.13 | $2.50 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 75.61 | 6.12 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.